Tai Stanley S
Department of Microbiology, College of Medicine, Howard University, Washington, DC 20059, USA.
Vaccines (Basel). 2016 Feb 22;4(1):4. doi: 10.3390/vaccines4010004.
Pneumococcal infection is one of the leading causes of death worldwide, especially in children of developing and underdeveloped countries. Capsular polysaccharide-based vaccines are available for the prevention of this disease. A 7-valent pneumococcal conjugate vaccine (PCV7) was licensed in 2000 for use in children less than two years of age. Subsequently, to broaden the protection, 10-valent (PCV10) and 13-valent (PCV13) vaccines were licensed in 2009 and 2010, respectively. All of these conjugate vaccines elicit an immune response that only provides protection against the infection of S. pneumoniae serotypes included in the formulation. Profiles of S. pneumoniae serotype distribution and serotype coverage for both PCV7 and PCV13 have been reported in some Asian countries/territories. But the published results cannot provide conclusive information due to the difference in studied population and geographic areas. The goals of this review are to obtain an accurate estimate of serotype coverage for PCV7, PCV10, and PCV13 and examine the change in the S. pneumoniae serotype distribution after PCV7 use among pediatric patients in East and Southeast Asia through the analysis of pooled data that were published in the English literature between 2000 and 2014.
肺炎球菌感染是全球主要死因之一，在发展中国家和不发达国家的儿童中尤为如此。基于荚膜多糖的疫苗可用于预防这种疾病。2000年，一种7价肺炎球菌结合疫苗（PCV7）被批准用于两岁以下儿童。随后，为了扩大保护范围，2009年和2010年分别批准了10价（PCV10）和13价（PCV13）疫苗。所有这些结合疫苗引发的免疫反应仅针对制剂中包含的肺炎链球菌血清型感染提供保护。一些亚洲国家/地区已报告了PCV7和PCV13的肺炎链球菌血清型分布及血清型覆盖率情况。但由于研究人群和地理区域的差异，已发表的结果无法提供确凿信息。本综述的目的是通过分析2000年至2014年期间发表在英文文献中的汇总数据，准确估计PCV7、PCV10和PCV13的血清型覆盖率，并研究东亚和东南亚儿科患者使用PCV7后肺炎链球菌血清型分布的变化。
